期刊
NANOMEDICINE
卷 12, 期 2, 页码 99-115出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2016-0325
关键词
amphotericin B; macrophage nanoparticle targeting; mannose receptors; thiolated chitosan; visceral leishmaniasis
资金
- UNESCO-L'Oreal International Fellowship for Young Women in Life Sciences
- NIH [P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103509] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH064570, P30MH062261] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034239, R01NS036126, P01NS031492, P01NS043985] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG043540] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [P01DA028555] Funding Source: NIH RePORTER
Aim: Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. Materials & methods: A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities. Results: MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 mu g/ml compared with 0.26 mu g/ml for native drug. Conclusion: These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据